Conference Menu

Short Course
PDF Download
Hotel & Travel
Sponsorship & Exhibits
Exhibit Contract
Mark your outlook
Press Pass
Request Brochure

Corporate Support Sponsor


Lead Sponsoring Publications

Nucleic Acid Therapeutics


Science AAAS

The Scientist

Sponsoring Publication



Media Partner

Genomeweb Logo

Thank you for your interest

Listen to the Podcast below, or view a Transcript of the Podcast here


The Resurgence of Oligonucleotide Therapeutics: A Podcast Discussing Challenges, Advances, and an Outlook for Success

with Dmitry Samarsky, Ph.D., Senior Vice President, Technology & Global Business Development, OliX Pharmaceuticals, Inc.

CHI recently interviewed Dr. Dmitry Samarsky, Senior Vice President of Technology and Global Business Development at OliX Pharmaceuticals, regarding the evolution of nucleic acid-based therapeutics; challenges within this space; recent advances in chemistry and delivery; and the greatest opportunities within this space over the next few years.

Discussion questions include:

1 Given the obvious benefit of oligonucleotide therapies being able to dramatically expand target space, why haven’t they impacted the drug development landscape as much as Biologics or small Molecules? What challenges have been encountered within this field?

2 It seems as if there has be a resurgence of interest in the discovery and development of oligonucleotide therapeutics. Why do you think this is? What has changed over the past few years?

3 You are hosting a workshop during the upcoming Oligonucleotide Therapeutics and Delivery conference, providing an overview of oligonucleotide therapeutics from discovery to manufacturing. Can you tell us more about this workshop? Who should attend this? What can they expect to learn during this?

4 Oligonucleotide therapeutics seem to be evolving rapidly, but in your opinion, where do you see the greatest opportunities within this space over the next few years?

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag